Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines: Adenovirus-vectored Vaccine Versus mRNA Vaccine

NCT05150834 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT05150834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05150834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines: Adenovirus-vectored Vaccine Versus mRNA Vaccine
Lead sponsor
Korea University Guro Hospital
Phase
Observational
Overall status
Unknown status
Start date
February 25, 2021
Completion date
December 31, 2023
Enrollment
53 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, immunogenicity, microbiome, sars-cov-2, vaccine